{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:15Z","timestamp":1753892055838,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study investigated the clinical effectiveness of molnupiravir for treating non-hospitalized COVID-19 patients with pre-existing psychiatric disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study used the TriNetX research network to identify patients with psychiatric disorder who experienced non-hospitalized COVID-19 between 1 January 2022, and 1 May 2023. The propensity score matching (PSM) method was used to match patients receiving molnupiravir (treated group) with those who did not (untreated group). The outcome included short-term outcomes - the composite of all-cause hospitalization or death within 30\u00a0days and the risk of post-COVID-19 conditions up to a year after COVID-19 diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two groups of 9,421 patients, each with balanced baseline characteristics, were identified using the PSM method. During the 30-day follow-up, treated group was associated with a reduced risk of hospitalization or mortality compared to untreated group (HR, 0.760; 95% CI, 0.665\u20130.869). Compared to untreated group, treated group also exhibited a decreased risk of experiencing post-COVID-19 conditions, including chest\/throat pain (HR, 0.615; 95% CI, 0.543\u20130.696), abnormal breathing (HR, 0.761; 95% CI, 0.687\u20130.884), abdominal symptoms (HR, 0.748; 95% CI, 0.674\u20130.831), fatigue (HR, 0.718; 95% CI, 0.638\u20130.808), headache (HR, 0.753; 95% CI, 0.665\u20130.852), cognitive symptoms (HR, 0.769; 95% CI, 0.630\u20130.940), myalgia (HR, 0.647; 95% CI, 0.530\u20130.789), cough (HR, 0.867; 95% CI, 0.770\u20130.978), and palpitation (HR, 0.641; 95% CI, 0.534\u20130.770) during the 1-year follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Molnupiravir could be associated with lower rates of all-cause hospitalization or death and also lower risk of post-COVID-19 condition among non-hospitalized COVID-19 patients with pre-existing psychiatric disorder.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1384264","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T04:56:03Z","timestamp":1720068963000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders"],"prefix":"10.3389","volume":"15","author":[{"given":"Ting-Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsuan-Yi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/M22-3565","article-title":"Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes","volume":"176","author":"Bajema","year":"2023","journal-title":"Ann. Intern Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.9758\/cpn.22.1014","article-title":"Drug-drug interaction between psychotropic medications and medications used in COVID-19: comparison of online databases","volume":"21","author":"Chatterjee","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.bbi.2023.08.024","article-title":"Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders","volume":"114","author":"Cheng","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11205-023-03111-y","article-title":"Vulnerabilities in mental health due to covid-19 pandemic: the response of the Italian physicians","volume":"168","author":"De Rose","year":"2023","journal-title":"Soc. Indic. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jinf.2023.02.012","article-title":"Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study","volume":"86","author":"Evans","year":"2023","journal-title":"J. Infect."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1038\/s41380-022-01562-2","article-title":"COVID-19 and severe mental illness in Israel: testing, infection, hospitalization, mortality and vaccination rates in a countrywide study","volume":"27","author":"Goldberger","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"Jama"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14787210.2023.2267846","article-title":"Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis","volume":"21","author":"Hsu","year":"","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jinf.2023.03.016","article-title":"The effect of molnupiravir on post-acute outcome of COVID-19 survivors","volume":"87","author":"Hsu","year":"","journal-title":"J. Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/j.jinf.2023.02.007","article-title":"Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors","volume":"86","author":"Hsu","year":"","journal-title":"J. Infect."},{"key":"B12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-2642434\/v1","article-title":"Treatment of mental disorders and the course of COVID-19","author":"Korzeniowska","year":"2023"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3201\/eid2807.212208","article-title":"Mental health conditions and severe COVID-19 outcomes after hospitalization, United States","volume":"28","author":"Koyama","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/v14081706","article-title":"The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Lai","year":"2022","journal-title":"Viruses"},{"key":"B17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.bbi.2023.09.008","article-title":"Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: a one-year retrospective cohort analysis of 33,908 patients","volume":"114","author":"Liu","year":"","journal-title":"Brain Behav. Immun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"afad204","DOI":"10.1093\/ageing\/afad204","article-title":"Real-world data analysis of post-COVID-19 condition risk in older patients","volume":"52","author":"Liu","year":"","journal-title":"Age Ageing"},{"key":"B19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jinf.2023.01.014","article-title":"The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients","volume":"86","author":"Liu","year":"","journal-title":"J. Infect."},{"key":"B20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/cid\/ciac781","article-title":"Effectiveness of molnupiravir in high-risk patients: a propensity score matched analysis","volume":"76","author":"Najjar-Debbiny","year":"","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1003773","DOI":"10.1371\/journal.pmed.1003773","article-title":"Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19","volume":"18","author":"Taquet","year":"","journal-title":"PLoS Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S2215-0366(20)30462-4","article-title":"Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA","volume":"8","author":"Taquet","year":"","journal-title":"Lancet Psychiatry"},{"volume-title":"Trinetx","year":"2023","key":"B24"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e29085","DOI":"10.1002\/jmv.29085","article-title":"Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data","volume":"95","author":"Tsai","year":"2023","journal-title":"J. Med. Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"100602","DOI":"10.1016\/j.lanwpc.2022.100602","article-title":"Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19","volume":"30","author":"Wai","year":"2023","journal-title":"Lancet Reg. Health West Pac"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","article-title":"Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study","volume":"22","author":"Wong","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"106984","DOI":"10.1016\/j.ijantimicag.2023.106984","article-title":"Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19","volume":"62","author":"Wu","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e074572","DOI":"10.1136\/bmj-2022-074572","article-title":"Molnupiravir and risk of post-acute sequelae of covid-19: cohort study","volume":"381","author":"Xie","year":"2023","journal-title":"bmj"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/ciac687","article-title":"Impact of the use of oral antiviral agents on the risk of hospitalization in community coronavirus disease 2019 patients (COVID-19)","volume":"76","author":"Yip","year":"2023","journal-title":"Clin. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1384264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T04:56:05Z","timestamp":1720068965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1384264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":30,"alternative-id":["10.3389\/fphar.2024.1384264"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1384264","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"article-number":"1384264"}}